Literature DB >> 29032412

Prognostication and Initiation of Therapy in Polycythemia Vera: Do We Have it Right?

Brady L Stein1,2, Srdan Verstovsek3.   

Abstract

ᅟ.

Entities:  

Keywords:  Myeloproliferative neoplasm; Polycythemia vera; Prognosis

Mesh：

Year:  2017        PMID： 29032412     DOI： 10.1007/s11899-017-0423-9

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


× No keyword cloud information.
  10 in total

1.  Some speculations on the myeloproliferative syndromes.

Authors:  W DAMESHEK
Journal:  Blood       Date:  1951-04       Impact factor: 22.113

Review 2.  Prologue: polycythemia vera. The closing of the Wasserman-Polycythemia Vera Study Group era.

Authors:  N I Berlin
Journal:  Semin Hematol       Date:  1997-01       Impact factor: 3.851

3.  Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.

Authors:  Srdan Verstovsek; Alessandro M Vannucchi; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Keita Kirito; Carlos Besses; Masayuki Hino; Beatriz Moiraghi; Carole B Miller; Mario Cazzola; Vittorio Rosti; Igor Blau; Ruben Mesa; Mark M Jones; Huiling Zhen; Jingjin Li; Nathalie Francillard; Dany Habr; Jean-Jacques Kiladjian
Journal:  Haematologica       Date:  2016-04-21       Impact factor: 9.941

Review 4.  Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms.

Authors:  Charles Elliott Foucar; Brady Lee Stein
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 5.  Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.

Authors:  Brady L Stein; Stephen T Oh; Dmitriy Berenzon; Gabriela S Hobbs; Marina Kremyanskaya; Raajit K Rampal; Camille N Abboud; Kenneth Adler; Mark L Heaney; Elias J Jabbour; Rami S Komrokji; Alison R Moliterno; Ellen K Ritchie; Lawrence Rice; John Mascarenhas; Ronald Hoffman
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

6.  Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

Authors:  Holly Geyer; Robyn Scherber; Heidi Kosiorek; Amylou C Dueck; Jean-Jacques Kiladjian; Zhijian Xiao; Stefanie Slot; Sonja Zweegman; Federico Sackmann; Ana Kerguelen Fuentes; Dolores Hernández-Maraver; Konstanze Döhner; Claire N Harrison; Deepti Radia; Pablo Muxi; Carlos Besses; Francisco Cervantes; Peter L Johansson; Bjorn Andreasson; Alessandro Rambaldi; Tiziano Barbui; Karin Bonatz; Andreas Reiter; Francoise Boyer; Gabriel Etienne; Jean-Christophe Ianotto; Dana Ranta; Lydia Roy; Jean-Yves Cahn; Norman Maldonado; Giovanni Barosi; Maria L Ferrari; Robert Peter Gale; Gunnar Birgegard; Zefeng Xu; Yue Zhang; Xiujuan Sun; Junqing Xu; Peihong Zhang; Peter A W te Boekhorst; Suzan Commandeur; Harry Schouten; Heike L Pahl; Martin Griesshammer; Frank Stegelmann; Thomas Lehmann; Zhenya Senyak; Alessandro M Vannucchi; Francesco Passamonti; Jan Samuelsson; Ruben A Mesa
Journal:  J Clin Oncol       Date:  2015-11-23       Impact factor: 44.544

7.  Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations.

Authors:  D Barraco; S Cerquozzi; C A Hanson; R P Ketterling; A Pardanani; N Gangat; A Tefferi
Journal:  Blood Cancer J       Date:  2017-03-10       Impact factor: 11.037

8.  Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease.

Authors:  Siddhartha Jaiswal; Pradeep Natarajan; Alexander J Silver; Christopher J Gibson; Alexander G Bick; Eugenia Shvartz; Marie McConkey; Namrata Gupta; Stacey Gabriel; Diego Ardissino; Usman Baber; Roxana Mehran; Valentin Fuster; John Danesh; Philippe Frossard; Danish Saleheen; Olle Melander; Galina K Sukhova; Donna Neuberg; Peter Libby; Sekar Kathiresan; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2017-06-21       Impact factor: 91.245

9.  Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.

Authors:  A Tefferi; E Rumi; G Finazzi; H Gisslinger; A M Vannucchi; F Rodeghiero; M L Randi; R Vaidya; M Cazzola; A Rambaldi; B Gisslinger; L Pieri; M Ruggeri; I Bertozzi; N H Sulai; I Casetti; A Carobbio; G Jeryczynski; D R Larson; L Müllauer; A Pardanani; J Thiele; F Passamonti; T Barbui
Journal:  Leukemia       Date:  2013-06-06       Impact factor: 11.528

10.  Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.

Authors:  Ruben A Mesa; Carole B Miller; Maureen Thyne; James Mangan; Sara Goldberger; Salman Fazal; Xiaomei Ma; Wendy Wilson; Dilan C Paranagama; David G Dubinski; Ahmad Naim; Shreekant Parasuraman; John Boyle; John O Mascarenhas
Journal:  Cancer       Date:  2016-09-30       Impact factor: 6.860
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.